This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
225 days left to bid. Opened 1 years ago, deadline 30 May 2027.
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
Develop medical countermeasures for CBRN threats with up to £4 million funding over 30 months, from prototype through Phase 2a clinical studies.
A three-year funded fellowship helping healthcare professionals with PhDs return to clinical research after extended career breaks.
Opportunity to provide a digital mental health platform delivering NICE-recommended therapeutic interventions and resources for children, young people, and families in South Staffordshire.
Opportunity for Primary Care Networks to deliver integrated COPD identification and specialist support services using digital risk stratification across Hull and East Yorkshire communities.
